全文获取类型
收费全文 | 519720篇 |
免费 | 34420篇 |
国内免费 | 639篇 |
专业分类
耳鼻咽喉 | 6956篇 |
儿科学 | 17089篇 |
妇产科学 | 13698篇 |
基础医学 | 86116篇 |
口腔科学 | 14652篇 |
临床医学 | 44931篇 |
内科学 | 94944篇 |
皮肤病学 | 12270篇 |
神经病学 | 36789篇 |
特种医学 | 18599篇 |
外国民族医学 | 63篇 |
外科学 | 77505篇 |
综合类 | 8505篇 |
一般理论 | 127篇 |
预防医学 | 39643篇 |
眼科学 | 12250篇 |
药学 | 40980篇 |
中国医学 | 1021篇 |
肿瘤学 | 28641篇 |
出版年
2018年 | 5196篇 |
2016年 | 4259篇 |
2015年 | 4771篇 |
2014年 | 6342篇 |
2013年 | 9906篇 |
2012年 | 13450篇 |
2011年 | 14808篇 |
2010年 | 8611篇 |
2009年 | 7998篇 |
2008年 | 14127篇 |
2007年 | 15044篇 |
2006年 | 15318篇 |
2005年 | 14709篇 |
2004年 | 14325篇 |
2003年 | 13652篇 |
2002年 | 13471篇 |
2001年 | 24099篇 |
2000年 | 25102篇 |
1999年 | 20581篇 |
1998年 | 5463篇 |
1997年 | 4722篇 |
1996年 | 5072篇 |
1995年 | 4648篇 |
1994年 | 4333篇 |
1992年 | 15735篇 |
1991年 | 16327篇 |
1990年 | 16427篇 |
1989年 | 15803篇 |
1988年 | 14583篇 |
1987年 | 14433篇 |
1986年 | 13603篇 |
1985年 | 12981篇 |
1984年 | 9645篇 |
1983年 | 8256篇 |
1982年 | 4573篇 |
1981年 | 4237篇 |
1979年 | 9424篇 |
1978年 | 6863篇 |
1977年 | 5780篇 |
1976年 | 5612篇 |
1975年 | 6401篇 |
1974年 | 7638篇 |
1973年 | 7138篇 |
1972年 | 6964篇 |
1971年 | 6688篇 |
1970年 | 6174篇 |
1969年 | 5890篇 |
1968年 | 5561篇 |
1967年 | 5014篇 |
1966年 | 4452篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
121.
JM Martín† L Calduch† C Monteagudo‡ I Molina† D Ramón† V Alonso† E Jordᆠ《Journal of the European Academy of Dermatology and Venereology》2006,20(4):428-431
Cutaneous plasmacytosis is a rare disorder characterized by a benign proliferation of mature plasma cells that appears as multiple dark-brown to purplish skin lesions, often associated with polyclonal hypergammaglobulinaemia. We present the case of a 55-year-old Caucasian man who suffered from a cutaneous plasmacytosis associated with two different carcinomas. Cutaneous plasmacytosis seems to be a reactive process because most cases reported are not associated with any apparent underlying disease. Nevertheless, because few reported cases were associated with malignancies, screening of additional neoplasms would be justified. 相似文献
122.
Christine E. Marx William T. Trost Lawrence J. Shampine Robert D. Stevens Christine M. Hulette David C. Steffens John F. Ervin Marian I. Butterfield Daniel G. Blazer Mark W. Massing Jeffrey A. Lieberman 《Neuropsychopharmacology》2006,60(12):1287-1294
BACKGROUND: Few data are currently available investigating neurosteroids (NS) in Alzheimer's disease (AD). The NS allopregnanolone may be decreased in serum and plasma in patients with AD, but it is unclear if allopregnanolone is also reduced in brain. Because a number of NS exhibit neuroprotective effects and impact cognitive performance in rodent models, these molecules may be relevant to the pathophysiology of neurodegenerative disorders. We therefore investigated prefrontal cortex (PFC) NS levels in AD. METHODS: Neurosteroid levels (allopregnanolone, pregnenolone, dehydroepiandrosterone [DHEA]) were determined in postmortem PFC in 14 male subjects with AD and 15 cognitively intact male control subjects by gas chromatography/mass spectrometry preceded by high-performance liquid chromatography purification. RESULTS: Subjects with AD exhibit significant reductions in allopregnanolone compared with cognitively intact control subjects (median levels = 2.50 ng/g vs. 5.59 ng/g, respectively; p = .02). Allopregnanolone levels are inversely correlated with neuropathological disease stage (Braak), r = -.49, p = .007. Median DHEA levels are elevated in subjects with AD (p = .01). CONCLUSIONS: Subjects with AD demonstrate significant reductions in PFC allopregnanolone levels, a finding that may be relevant to neuropathological disease stage severity. Neurosteroids may have utility as candidate biomarkers in AD. 相似文献
123.
124.
Published data devoted to making and characterization of the properties of polymeric wound dressings with proteolytic action
are reviewed. These data are indicative of individual dependence of the physicochemical properties, activity, and stability
of each particular enzyme on the type of polymer matrix and the method of immobilization. In order to obtain wound dressings,
which are active in physiological medium and retain their activity upon sterilization, it is necessary to optimize the composition
and characteristics of a polymer matrix and the enzyme included into its structure.
__________
Translated from Khimiko-Farmatsevticheskii Zhurnal, Vol. 40, No. 8, pp. 24–28, August, 2006. 相似文献
125.
R H Green C E Brightling S McKenna B Hargadon N Neale D Parker C Ruse I P Hall I D Pavord 《The European respiratory journal》2006,27(6):1144-1151
There is increasing evidence that the assessment of eosinophilic airway inflammation using induced sputum and measurement of airway hyperresponsiveness provides additional, clinically important information concerning asthma control. The aim of this study was to directly compare the effects of different treatments on these markers in patients with asthma and persistent symptoms, despite the use of low-dose inhaled corticosteroids. A double-blind four-way crossover study was performed, which compared a 1-month treatment with budesonide 400 mug b.i.d., additional formoterol, additional montelukast and placebo in 49 patients with uncontrolled asthma despite budesonide 100 mug b.i.d., with each treatment separated by a 4-week washout period. The change in sputum eosinophil count with formoterol (2.4 to 3.8% change, 0.6-fold reduction, 95% confidence interval (CI) 0.5-0.9) differed significantly from placebo (2.8 to 2.5% change, 1.1-fold reduction, 95% CI 0.7-1.6) and high-dose budesonide (2.7 to 1.6% change, 1.6-fold reduction, 95% CI 1.2-2.2). The effects of montelukast did not differ from placebo. The changes in methacholine airway responsiveness were small and did not differ between treatments. High-dose budesonide had the broadest range of beneficial effects on other outcomes, including symptom scores, morning peak expiratory flow and forced expiratory volume in one second. In conclusion, treatment given in addition to low-dose inhaled corticosteroids results in modest benefits. Formoterol and high-dose budesonide have contrasting effects on eosinophilic airway inflammation. 相似文献
126.
J Müller-Quernheim K I Gaede E Fireman G Zissel 《The European respiratory journal》2006,27(6):1190-1195
An increase in chronic beryllium disease (CBD) has been suggested due to higher industrial use of beryllium alloys. Since occupational CBD is a perfect phenocopy of sarcoidosis, it might be misdiagnosed as sarcoidosis. In the current it was hypothesised that CBD exists in cohorts of sarcoidosis patients. In a prospective case study, sarcoidosis patients were evaluated for potential beryllium exposure. In those patients in whom beryllium exposure was confirmed and beryllium hypersensitivity demonstrated, the diagnosis of sarcoidosis was rejected and corrected to CBD. In 84 patients seen for re-evaluation or making a diagnosis of sarcoidosis, beryllium exposure was recognised and a diagnosis of CBD was made in 34 out of 84 patients. The time lag between clinical diagnosis of sarcoidosis and the final diagnosis of CBD ranged 0-18 yrs (median 3 yrs) and the mean (range) age at time of diagnosis of CBD was 43.9(25-80) yrs. Beryllium-contaminated workplaces causing disease encompassed a wide spectrum of industries and technical trades in which beryllium-exposure is generally not perceived as a health hazard. In conclusion, chronic beryllium disease still belongs to the spectrum of differential diagnoses of granulomatous disorders. 相似文献
127.
128.
129.
Erika E Forbes Douglas E Williamson Neal D Ryan Boris Birmaher David A Axelson Ronald E Dahl 《Neuropsychopharmacology》2006,59(1):24-30
BACKGROUND: Changes in the hypothalamic-pituitary-adrenal (HPA) axis, as evidenced by patterns of cortisol secretion, have been of interest in understanding depression and anxiety disorders across the life span. Previous studies of pediatric depression have pointed to the period around sleep onset as a key time point for observing alterations in cortisol secretion associated with affective disorders. Evidence also indicates that pubertal development may influence the expression of HPA dysregulation. We hypothesized that adolescents with depression and youth with anxiety disorders exhibit elevated peri-sleep-onset cortisol. METHODS: Plasma cortisol was sampled every 20 min around sleep onset from children and adolescents with major depressive disorder (n = 116), anxiety disorders (n = 32), or no history of psychiatric disorder (control; n = 76). Sleep onset was determined by polysomnography. Classification of participants as children or adolescents was based on Tanner staging of pubertal maturation. RESULTS: Children with anxiety disorders had higher peri-sleep-onset cortisol than children with depression or control children. Adolescents with depression had marginally higher peri-sleep-onset cortisol than control adolescents and significantly higher peri-sleep-onset cortisol than children with depression. CONCLUSIONS: Depression and anxiety are associated with altered cortisol secretion around sleep onset, and these changes appear to be influenced by pubertal maturation. 相似文献
130.